Apex Biotechnology Corp. (1733) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Apex Biotechnology Corp. (1733:TWSE), powered by AI.

Current Price
$29.35
Sector
Healthcare
What is the Apex Biotechnology Corp. stock price forecast?

Apex Biotechnology Corp. is currently trading at $29.35. View real-time AI analysis on Alpha Lenz.

What is Apex Biotechnology Corp. insider trading activity?

View the latest insider trading data for Apex Biotechnology Corp. on Alpha Lenz.

What is Apex Biotechnology Corp.'s P/E ratio?

View Apex Biotechnology Corp.'s valuation metrics on Alpha Lenz.

Apex Biotechnology Corp.

TWSE · 1733
NT$29.35+0.10(+0.34%)
Ask about Apex Biotechnology Corp.'s future dividend policy...
Alpha Chat Insight

Apex Biotechnology Corp.'s ROE is 8.8%. Explore profitability and growth together.

Ask for details

Company Overview

Apex Biotechnology Corp. is a leading player in the life sciences sector, primarily engaged in the research, development, and commercialization of innovative biotechnological solutions. The company focuses on creating advanced therapeutic tools and diagnostic products that address a wide array of health challenges, including metabolic, infectious, and genetic diseases. Apex Biotechnology Corp. stands out with its commitment to pioneering technologies such as CRISPR-based gene editing, personalized medicine, and cutting-edge bioinformatics. With a global reach, the company's products not only serve medical professionals and patients but also significantly impact sectors like pharmaceuticals, diagnostics, and healthcare services. Apex Biotechnology Corp. plays a crucial role in the financial market as a representative of the biotechnology industry's dynamic and high-growth potential. The company actively collaborates with research institutions and pharmaceutical giants to stay at the forefront of scientific breakthroughs, thus maintaining its market relevance and contributing to advancements in public health measures.

CEODr. Yanshi Shen Ph.D.
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$1.94BRevenue
0.00Shares Out
0Employees

Margins

27.70%Gross
13.81%EBITDA
7.97%Operating
9.76%Pre-Tax
8.38%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-4.66%Rev 3Yr
-0.61%Rev 5Yr
-4.24%Op Inc 3Yr
8.53%Op Inc 5Yr
-3.50%Net Inc 3Yr
11.49%Net Inc 5Yr

Returns

6.74%ROA
8.82%ROE
7.99%ROIC

Financial Health

NT$567.09MCash & Cash Equivalents
NT$-21.78MNet Debt
29.15%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Apex Biotechnology Corp. (ticker: 1733) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 29.35 with a P/E ratio of -x and P/B of -x.

ROE is 8.82% and operating margin is 7.97%. Annual revenue is $1.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Apex Biotechnology Corp. (1733) Stock Forecast 2026 $29.35 — Price, Financials & Analyst Targets | Alpha Lenz